[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-mi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-mi":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100623979","cardiovascular-kidney-and-metabolic-health-assessment-and-patient-empowerment-100623979",false,"NCT07403669","Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment","Cardiovascular Kidney and Metaboolic (CKM) Health Assessment and Patient Empowerment in chROnic Disease Using a Health Coach INtervention ModEl: A Randomized Clinical Trial","CHAPERONE-CKM","Inclusion Criteria:\n\n* Men and women over 18 years of age are included\n* Eligible subjects must have one of the risk factor\u002F disease component of CKM:\n* Diabetes with A1C of 7.5 or higher;\n* or Heart disease with stent placement;\n* or Coronary Artery Bypass Graft (CABG) in the last 12 months;\n* or Chronic Kidney Disease (CKD) stage 2- 4\n* and, in those with Heart failure, a recent hospitalization within one week of enrollment is required\n\nExclusion Criteria:\n\n* Those subjects who are not willing to sign an informed consent","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.",[27,28,29,30],"Acute MI","Heart Failure","Diabetes Mellitus","Kidney Disease","RECRUITING","2026-02-10",{"date":34,"type":35},"2026-02-12","ACTUAL",{"date":37,"type":35},"2025-10-22",{"date":39,"type":21},"2027-04-22",{"name":41,"class":42},"Aventyn, Inc.","INDUSTRY",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100431980","care-coordination-to-assess-improvement-in-outcomes-in-hospital-readmissions-100431980","NCT04905160","Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions","Care cOordination Using Mobile Technology to Enhance Patient Empowerment in Acute Comorbidities to aSSess Improvement in Outcomes in Hospital readmissioNs","COMPASSION","Inclusion Criteria:\n\nMen and women over 18 years of age are included. Eligible subjects must be hospitalized with a primary diagnosis of ADHF or acute MI. The diagnosis of HF is established by the presence of typical symptoms, signs, and objective evidence of pulmonary congestion, elevated BNP or N-terminal pro B-type natriuretic peptide (NT-pro BNP) or impaired cardiac function. Acute MI is diagnosed by presence of chest pain, arm pain, or dyspnea with elevated Troponin and\u002For EKG changes suggestive of Acute coronary syndrome requiring intervention or optimal medical therapy.\n\nExclusion Criteria:\n\n1. Study informed consent will be obtained before enrollment in the study for Phase 1 and Phase 2\n2. All subjects 18 years or above will be a criteria for inclusion for Phase 1\n3. For Phase 2, men and women 50 years or older with positive Covid19 antigen test and one other risk factor as mentioned in the comorbid section of workflow will be enrolled in the intervention arm of the study;\n4. For phase 2, subjects should be able to be randomized within 48 hours of Covid19 antigen positive status\n5. Patients considered unreliable by the investigator concerning the requirements for follow-up visits",true,{"count":54,"type":21},1000,[24],"Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and\u002For right ventricular filling pressures and decreased cardiac output.",[28,58,27],"ADHF","2024-03-19",{"date":61,"type":35},"2024-03-20",{"date":63,"type":35},"2021-02-18",{"date":65,"type":21},"2026-12-22",{"name":41,"class":42},1,"Acute-MI"]